Network Version
Sunifiram Data Sheet
| Product Name: | Sunifiram |
 |
|---|---|---|
| CAS No.: | 314728-85-3 | |
| Cat. No.: | HY-17550 | |
| MWt: | 246.3 | |
| Formula: | C14H18N2O2 | |
| Purity : | >98% | |
| Solubility: | H<sub>2</sub>O : 50 mg/mL (ultrasonic);DMSO : ≥ 2.6 mg/mL | |
| Mechanisms: | Target: Neurological Disease | |
| Biological Activity: | ||
| Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585). Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD)[1][2][3][4]. In Vitro:Sunifiram (0.01-1 μM, 30 minutes) reduced the antagonistic effect of kynurenic acid on NMDA and increased NMDA activity[4]. In Vivo:Sunifiram (0.001-0.1 mg/kg, p.o. or i.v., single dose, 20 minutes prior) is able to prevent amnesia in a scopolamine (HY-N0296)-induced amnesia mouse model[4]. | ||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com